Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02

Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Centene (CNC) Tops Q1 EPS by 18c; Raises guidance
• Ball Corporation (BALL) Tops Q1 EPS by 12c